{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T13:50:53Z","timestamp":1783691453368,"version":"3.55.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ejmech.2023.115703","type":"journal-article","created":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T23:30:34Z","timestamp":1691105434000},"page":"115703","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Design, synthesis, and biological evaluation of 1,6-naphthyridine-2-one derivatives as novel FGFR4 inhibitors for the treatment of colorectal cancer"],"prefix":"10.1016","volume":"259","author":[{"given":"Bo","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinshuang","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zefeng","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peipei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunjie","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaokun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiguo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2023.115703_bib1","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1038\/s41418-019-0312-y","article-title":"Gut microbiota-stimulated cathepsin K secretion mediates TLR4-dependent M2 macrophage polarization and promotes tumor metastasis in colorectal cancer","volume":"26","author":"Li","year":"2019","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ejmech.2023.115703_bib2","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3390\/cancers15020383","article-title":"New frontiers in colorectal cancer treatment combining nanotechnology with photo- and radiotherapy","volume":"15","author":"Freitas","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2023.115703_bib3","article-title":"Global colorectal cancer burden in 2020 and projections to 2040, Transl","volume":"14","author":"Xi","year":"2021","journal-title":"Oncol."},{"key":"10.1016\/j.ejmech.2023.115703_bib4","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nrc.2016.126","article-title":"Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer","volume":"17","author":"Dienstmann","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2023.115703_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113219","article-title":"Design, synthesis, and biological evaluation of indazole derivatives as selective and potent FGFR4 inhibitors for the treatment of FGF19-driven hepatocellular cancer","volume":"214","author":"Chen","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115703_bib6","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1021\/acs.jmedchem.8b01531","article-title":"Fibroblast growth factor receptor 4 (FGFR4) selective inhibitors as hepatocellular carcinoma therapy: advances and prospects","volume":"62","author":"Lu","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115703_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063695","article-title":"FGFR4 role in epithelial-mesenchymal transition and its therapeutic value in colorectal cancer","volume":"8","author":"Pel\u00e1ez-Garc\u00eda","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2023.115703_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110374","article-title":"BCL-XL inhibition induces an FGFR4-mediated rescue response in colorectal cancer","volume":"38","author":"Ramesh","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2023.115703_bib9","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3390\/diagnostics11060978","article-title":"Impact of FGFR4 gene polymorphism on the progression of colorectal cancer","volume":"11","author":"Shiu","year":"2021","journal-title":"Diagnostics"},{"key":"10.1016\/j.ejmech.2023.115703_bib10","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O'Hare","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2023.115703_bib11","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1158\/1535-7163.MCT-11-0306","article-title":"A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models","volume":"10","author":"Zhao","year":"2011","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2023.115703_bib12","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1158\/1535-7163.MCT-16-0589","article-title":"Discovery and pharmacological characterization of JNJ-42756493 (Erdafitinib), a functionally selective small-molecule FGFR family inhibitor","volume":"16","author":"Perera","year":"2017","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2023.115703_bib13","doi-asserted-by":"crossref","first-page":"6516","DOI":"10.1021\/acs.jmedchem.7b00360","article-title":"Discovery of the irreversible covalent FGFR inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the treatment of solid tumors","volume":"60","author":"Brameld","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115703_bib14","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1158\/2159-8290.CD-14-1029","article-title":"First selective small molecule inhibitor of FGFR4 for the treatment of hepatocellular carcinomas with an activated FGFR4 signaling pathway","volume":"5","author":"Hagel","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2023.115703_bib15","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1158\/2159-8290.CD-19-0555","article-title":"First-in-Human phase I study of Fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma","volume":"9","author":"Kim","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2023.115703_bib16","doi-asserted-by":"crossref","first-page":"12542","DOI":"10.1021\/acs.jmedchem.0c01019","article-title":"Discovery of Roblitinib (FGF401) as a reversible-covalent inhibitor of the kinase activity of fibroblast growth factor receptor 4","volume":"63","author":"Fairhurst","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115703_bib17","doi-asserted-by":"crossref","first-page":"6999","DOI":"10.1158\/0008-5472.CAN-17-1865","article-title":"H3B-6527 is a potent and selective inhibitor of FGFR4 in FGF19-driven hepatocellular carcinoma","volume":"77","author":"Joshi","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2023.115703_bib18","doi-asserted-by":"crossref","first-page":"11484","DOI":"10.1021\/acs.jmedchem.0c00044","article-title":"Development of a potent and specific FGFR4 inhibitor for the treatment of hepatocellular carcinoma","volume":"63","author":"Rezende Miranda","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115703_bib19","doi-asserted-by":"crossref","first-page":"7595","DOI":"10.1021\/acs.jmedchem.1c01977","article-title":"Discovery of 1,6-naphthyridin-2(1H)-one derivatives as novel, potent, and selective FGFR4 inhibitors for the treatment of hepatocellular carcinoma","volume":"65","author":"Zhang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115703_bib20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3390\/cells8010031","article-title":"Fibroblast growth factor receptor 4 targeting in cancer: new insights into mechanisms and therapeutic strategies","volume":"8","author":"Lang","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2023.115703_bib21","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrc1647","article-title":"The role of focal-adhesion kinase in cancer - a new therapeutic opportunity","volume":"5","author":"McLean","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2023.115703_bib22","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1080\/19336918.2019.1685928","article-title":"Paracrine signalling of AGR2 stimulates RhoA function in fibroblasts and modulates cell elongation and migration","volume":"13","author":"Mangukiya","year":"2019","journal-title":"Cell Adhes. Migrat."},{"key":"10.1016\/j.ejmech.2023.115703_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021482","article-title":"Endothelial cell-specific molecule 2 (ECSM2) localizes to cell-cell junctions and modulates bFGF-directed cell migration via the ERK-FAK pathway","volume":"6","author":"Shi","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2023.115703_bib24","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s40478-022-01363-2","article-title":"Fibroblast growth factor receptor 4 promotes glioblastoma progression: a central role of integrin-mediated cell invasiveness","volume":"10","author":"Gabler","year":"2022","journal-title":"Acta Neuropathol. Com."},{"key":"10.1016\/j.ejmech.2023.115703_bib25","first-page":"2417","article-title":"Immunohistochemical analyses of focal adhesion kinase expression in benign and malignant human breast and colon tissues: correlation with preinvasive and invasive phenotypes","volume":"6","author":"Cance","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2023.115703_bib26","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/carcin\/bgm202","article-title":"FGF18 in colorectal tumour cells: autocrine and paracrine effects","volume":"29","author":"Sonvilla","year":"2008","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ejmech.2023.115703_bib27","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s10822-011-9533-y","article-title":"Docking benchmarks and real-world application","volume":"26","author":"Spitzer","year":"2012","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.ejmech.2023.115703_bib28","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3390\/md17020074","article-title":"Characterization of the specific mode of action of a chitin deacetylase and separation of the partially acetylated chitosan oligosaccharides","volume":"17","author":"Zhu","year":"2019","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.ejmech.2023.115703_bib29","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.3390\/molecules23123307","article-title":"Evaluation of the novel synthetic tyrosinase inhibitor (Z)-3-(3-bromo-4-hydroxybenzylidene)thiochroman-4-one (MHY1498) in vitro and in silico","volume":"23","author":"Bang","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2023.115703_bib30","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1021\/acs.jmedchem.1c01732","article-title":"Discovery of potent and orally bioavailable platelet-derived growth factor receptor (PDGFR) inhibitors for the treatment of osteosarcoma","volume":"65","author":"Chen","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115703_bib31","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.3390\/biom11091348","article-title":"Inhibition of UBA5 expression and induction of autophagy in breast cancer cells by Usenamine A","volume":"11","author":"Fang","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejmech.2023.115703_bib32","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1423-0127-20-13","article-title":"Pentoxifylline and the proteasome inhibitor MG132 induce apoptosis in human leukemia U937 cells through a decrease in the expression of Bcl-2 and Bcl-XL and phosphorylation of p65","volume":"20","author":"Bravo-Cuellar","year":"2013","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.ejmech.2023.115703_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2022.110200","article-title":"Cyy260 suppresses the proliferation, migration and tumor growth of osteosarcoma by targeting PDGFR-\u03b2 signaling pathway","volume":"367","author":"Qiu","year":"2022","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ejmech.2023.115703_bib34","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.3724\/abbs.2022139","article-title":"Cyy-287, a novel pyrimidine-2,4-diamine derivative, inhibits tumor growth of EGFR-driven non-small cell lung cancer via the ERK pathway","volume":"54","author":"Zhang","year":"2022","journal-title":"Acta Biochim. Biophys. Sin."}],"updated-by":[{"DOI":"10.1016\/j.ejmech.2024.116230","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000}}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423006700?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423006700?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:01:32Z","timestamp":1759330892000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423006700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":34,"alternative-id":["S0223523423006700"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115703","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and biological evaluation of 1,6-naphthyridine-2-one derivatives as novel FGFR4 inhibitors for the treatment of colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115703","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115703"}}